Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Simulations Plus, Inc. - Common Stock (NQ: SLP )

29.92 +0.08 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the BTIG Digital Health Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Stephens Annual Investment Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases DILIsym® X
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® Version 12
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
From QHP Capital
Via Business Wire
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Inc. (NASDAQ: SLP) Near the Top of Equities by Percentage Gain on 4/4
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Bath Awarded New FDA Grant
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.